A critical literature review of health economic evaluations of rotavirus vaccination

References

• Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003; 81:197 - 204; PMID: 12764516
   PubMed Web of Science ®Google Scholar
• Santosham M, Chandran A, Fitzwater S, Fischer-Walker C, Baqui AH, Black R. Progress and barriers for the control of diarrhoeal disease. Lancet 2010; 376:63 - 7; http://dx.doi.org/10.1016/S0140-6736(10)60356-X; PMID: 20609988
   PubMed Web of Science ®Google Scholar
• Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565 - 72; http://dx.doi.org/10.3201/eid0905.020562; PMID: 12737740
   PubMed Web of Science ®Google Scholar
• Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006; 12:304 - 6; http://dx.doi.org/10.3201/eid1202.050006; PMID: 16494759
   PubMed Web of Science ®Google Scholar
• Soriano-Gabarró M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006; 25:Suppl S7 - 11; http://dx.doi.org/10.1097/01.inf.0000197622.98559.01; PMID: 16397431
   PubMed Web of Science ®Google Scholar
• Bilcke J, Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009; 27:281 - 97; http://dx.doi.org/10.2165/00019053-200927040-00002; PMID: 19485425
   PubMed Web of Science ®Google Scholar
• Tu HA, Woerdenbag HJ, Kane S, Rozenbaum MH, Li SC, Postma MJ. Economic evaluations of rotavirus immunization for developing countries: a review of the literature. Expert Rev Vaccines 2011; 10:1037 - 51; http://dx.doi.org/10.1586/erv.11.65; PMID: 21806398
   PubMed Web of Science ®Google Scholar
• Plosker GL. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries. Pharmacoeconomics 2011; 29:439 - 54; http://dx.doi.org/10.2165/11207130-000000000-00000; PMID: 21504245
   PubMed Web of Science ®Google Scholar
• Plosker GL. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in developed countries. Drugs R D 2012; 12:239 - 44; http://dx.doi.org/10.2165/11208130-000000000-00000; PMID: 23017130
   PubMedGoogle Scholar
• Plosker GL. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries. Pharmacoeconomics 2011; 29:989 - 1009; http://dx.doi.org/10.2165/11207210-000000000-00000; PMID: 21988293
   PubMed Web of Science ®Google Scholar
• Plosker GL. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis in developing countries. Paediatr Drugs 2012; 14:429 - 33; PMID: 23013458
   PubMedGoogle Scholar
• Postma MJ, Jit M, Rozenbaum MH, Standaert B, Tu HA, Hutubessy RC. Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world. BMC Med 2011; 9:84; http://dx.doi.org/10.1186/1741-7015-9-84; PMID: 21740545
   PubMed Web of Science ®Google Scholar
• Fruytier AC, Van Schoor J, Standaert B. Vaccination with RIX4414 is cost-effective in a Belgian setting. Value Health 2006; 9:Issue 6 A253; http://dx.doi.org/10.1016/S1098-3015(10)63361-X
   PubMedGoogle Scholar
• Dhont P, Trichard M, Largeron N, Rafia R, Bénard S. Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium. J Med Econ 2008; 11:431 - 48; http://dx.doi.org/10.3111/13696990802306162; PMID: 19450097
   PubMedGoogle Scholar
• Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and “no medical care” disease impact in Belgium. Med Decis Making 2009; 29:33 - 50; http://dx.doi.org/10.1177/0272989X08324955; PMID: 18948433
   PubMed Web of Science ®Google Scholar
• Nohynek H, Salo H, Renko M, Leino T. Finland introduces rotavirus vaccine into the national vaccination programme in September 2009. Euro Surveill 2009; 14:1 - 3; PMID: 19728979
   PubMedGoogle Scholar
• Trichard M, Largeron N, Soum S, Saint-Sardos C. Budget impact of a universal rotavirus vaccination programme with Rotateq® in France. Value Health 2007; 10:A352; http://dx.doi.org/10.1016/S1098-3015(10)65253-9
   Google Scholar
• Huet F, Largeron N, Trichard M, Miadi-Fargier H, Jasso-Mosqueda G. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France. Vaccine 2007; 25:6348 - 58; http://dx.doi.org/10.1016/j.vaccine.2007.06.015; PMID: 17629598
   PubMed Web of Science ®Google Scholar
• Melliez H, Levybruhl D, Boelle PY, Dervaux B, Baron S, Yazdanpanah Y. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008; 26:706 - 15; http://dx.doi.org/10.1016/j.vaccine.2007.11.064; PMID: 18166250
   PubMed Web of Science ®Google Scholar
• Standaert B, Parez N, Tehard B, Colin X, Detournay B. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Appl Health Econ Health Policy 2008; 6:199 - 216; http://dx.doi.org/10.1007/BF03256134; PMID: 19382820
   PubMedGoogle Scholar
• Benard S, Quilici S. Economic evaluation of a pentavalent universal rotavirus vaccination programme in France. European Society for Paediatric Infectious Diseases 27th Annual Meeting. Brussels (Belgium), June 9-13, 2009.
   Google Scholar
• Hammerschmidt T, Forster J, Huppertz HI, Heininger U, Roos R, Standaert B. Epidemiological and economic impact of routine vaccination of infants against rotavirus gastroenteritis in Germany: a preliminary analysis. Value Health 2010; 13:A435 - 6
   Google Scholar
• Buesch K, Ezzat N, Trichard M, Largeron N. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal vaccination programme in Germany. Value Health 2007; 10:Issue 6 A437; http://dx.doi.org/10.1016/S1098-3015(10)65514-3
   Google Scholar
• Greiner W. Potential health and economic outcomes of implementing universal rotavirus vaccination programme with Rotateq® in Europe - the example of Germany. European Society for Paediatric Infectious Diseases 26th Annual Meeting. Graz (Austria), May 13-17, 2008.
   Google Scholar
• Brüggenjürgen B, Schmitter S, Ezzat N, Quilici S. Economic evaluation of universal pentavalent rotavirus vaccination programme in Germany. European Society for Paediatric Research 50th Annual Meeting. Hamburg (Germany), October 9-12, 2009.
   Google Scholar
• Syriopoulou V, Kafetzis D, Theodoridou M, Syrogiannopoulos GA, Mantagos S, Trimis G, et al. Evaluation of potential medical and economic benefits of universal rotavirus vaccination in Greece. Acta Paediatr 2011; 100:732 - 9; http://dx.doi.org/10.1111/j.1651-2227.2010.02127.x; PMID: 21223372
   PubMed Web of Science ®Google Scholar
• Redmond S, Standaert B. Cost-effectiveness of universal rotavirus vaccination in Ireland: a preliminary analysis. Value Health 2009; 12:A423; http://dx.doi.org/10.1016/S1098-3015(10)75090-7
   Google Scholar
• Tilson L, Jit M, Schmitz S, Walsh C, Garvey P, McKeown P, et al. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine 2011; 29:7463 - 73; http://dx.doi.org/10.1016/j.vaccine.2011.07.056; PMID: 21821085
   PubMed Web of Science ®Google Scholar
• Panatto D, Amicizia D, Ansaldi F, Marocco A, Marchetti F, Bamfi F, et al. Burden of rotavirus disease and cost-effectiveness of universal vaccination in the Province of Genoa (Northern Italy). Vaccine 2009; 27:3450 - 3; http://dx.doi.org/10.1016/j.vaccine.2009.01.054; PMID: 19200850
   PubMed Web of Science ®Google Scholar
• Giammanco MD, Coniglio MA, Pignato S, Giammanco G. An economic analysis of rotavirus vaccination in Italy. Vaccine 2009; 27:3904 - 11; http://dx.doi.org/10.1016/j.vaccine.2009.04.002; PMID: 19446934
   PubMed Web of Science ®Google Scholar
• Welte R, Jager J, van Duynhoven Y, de Wit M. Economic evaluation of rotavirus vaccination for the Netherlands. Value Health 2001; 4:131 - 131; http://dx.doi.org/10.1046/j.1524-4733.2001.40202-171.x
   Google Scholar
• Goossens LM, Standaert B, Hartwig N, Hövels AM, Al MJ. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008; 26:1118 - 27; http://dx.doi.org/10.1016/j.vaccine.2007.11.070; PMID: 18215445
   PubMed Web of Science ®Google Scholar
• Zomer TP, van Duynhoven YT, Mangen MJ, van der Maas NA, Vennema H, Boot H, et al. Assessing the introduction of universal rotavirus vaccination in the Netherlands. Vaccine 2008; 26:3757 - 64; http://dx.doi.org/10.1016/j.vaccine.2008.04.039; PMID: 18514975
   PubMed Web of Science ®Google Scholar
• Mangen MJ, van Duynhoven YT, Vennema H, van Pelt W, Havelaar AH, de Melker HE. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?. Vaccine 2010; 28:2624 - 35; http://dx.doi.org/10.1016/j.vaccine.2010.01.014; PMID: 20109593
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ, Consensus Group on Dutch Rotavirus Vaccination (CoRoVa-Group). Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health 2011; 11:462; http://dx.doi.org/10.1186/1471-2458-11-462; PMID: 21663620
   PubMed Web of Science ®Google Scholar
• André S, Silva C, Mateus MC, Standaert B. Cost-effectiveness of vaccination with Rotarix in Portugal. Europaediatrics 3rd Annual Meeting. Istanbul (Turkey), June 14-17 2008.
   Google Scholar
• Rubio-Terres C, Martin-Escudero V, Standaert B, Rodrigo C. Cost impact of paediatric rotavirus gastroenteritis (RVGE) and potential benefits of a universal vaccination programme in Spain. European Society for Paediatric Infectious Diseases 26th Annual Meeting. Graz (Austria), May 13-17, 2008.
   Google Scholar
• Pérez-Rubio A, Luquero FJ, Eiros Bouza JM, Castrodeza Sanz JJ, Bachiller Luque MR, de Lejarazu RO, et al. Socio-economic modelling of rotavirus vaccination in Castilla y Leon, Spain. Infez Med 2011; 19:166 - 75; PMID: 22037437
   PubMedGoogle Scholar
• Largeron N, Trichard M, Miadi-Fargier H, Trancart A, D’Ausilio A, Chicoye A. Cost-effectiveness analysis of rotavirus vaccination programme in the UK. Value Health 2006; 9:Issue 6 A243 - 4; http://dx.doi.org/10.1016/S1098-3015(10)63332-3
   Google Scholar
• Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 2007; 25:3971 - 9; http://dx.doi.org/10.1016/j.vaccine.2007.02.070; PMID: 17400341
   PubMed Web of Science ®Google Scholar
• Lorgelly PK, Joshi D, Iturriza Gómara M, Gray J, Mugford M. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2008; 136:44 - 55; http://dx.doi.org/10.1017/S0950268807008151; PMID: 17335631
   PubMed Web of Science ®Google Scholar
• Martin A, Batty A, Roberts JA, Standaert B. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. Vaccine 2009; 27:4520 - 8; http://dx.doi.org/10.1016/j.vaccine.2009.05.006; PMID: 19446594
   PubMed Web of Science ®Google Scholar
• Jit M, Bilcke J, Mangen MJ, Salo H, Melliez H, Edmunds WJ, et al. The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine 2009; 27:6121 - 8; http://dx.doi.org/10.1016/j.vaccine.2009.08.030; PMID: 19715781
   PubMed Web of Science ®Google Scholar
• Jit M, Mangen MJ, Melliez H, Yazdanpanah Y, Bilcke J, Salo H, et al. An update to “The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe”. Vaccine 2010; 28:7457 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.08.060; PMID: 20846529
   PubMed Web of Science ®Google Scholar
• de Soárez PC, Valentim J, Sartori AM, Novaes HM. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica 2008; 23:221 - 30; http://dx.doi.org/10.1590/S1020-49892008000400001; PMID: 18505602
   PubMed Web of Science ®Google Scholar
• Constenla DO, Linhares AC, Rheingans RD, Antil LR, Waldman EA, da Silva LJ. Economic impact of a rotavirus vaccine in Brazil. J Health Popul Nutr 2008; 26:388 - 96; PMID: 19069617
   PubMed Web of Science ®Google Scholar
• Valentim – Estimates in the economic evaluations of vaccination programmes: the cases of rotavirus and varicella in Brazil. Value Health 2009; 12:Issue 7 A427; http://dx.doi.org/10.1016/S1098-3015(10)75110-X
   Google Scholar
• Constenla D, O’Ryan M, Navarrete MS, Antil L, Rheingans RD. [Potential cost effectiveness of a rotavirus vaccine in Chile]. Rev Med Chil 2006; 134:679 - 88; http://dx.doi.org/10.4067/S0034-98872006000600002; PMID: 17130941
   PubMed Web of Science ®Google Scholar
• De la Hoz F, Alvis N, Narváez J, Cediel N, Gamboa O, Velandia M. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia. Vaccine 2010; 28:3856 - 64; http://dx.doi.org/10.1016/j.vaccine.2010.03.004; PMID: 20347057
   PubMed Web of Science ®Google Scholar
• Valencia-Mendoza A, Bertozzi SM, Gutierrez JP, Itzler R. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico. BMC Infect Dis 2008; 8:103 - 16; http://dx.doi.org/10.1186/1471-2334-8-103; PMID: 18664280
   PubMed Web of Science ®Google Scholar
• Constenla D, Velázquez FR, Rheingans RD, Antil L, Cervantes Y. Economic impact of a rotavirus vaccination program in Mexico. Rev Panam Salud Publica 2009; 25:481 - 90; http://dx.doi.org/10.1590/S1020-49892009000600003; PMID: 19695142
   PubMed Web of Science ®Google Scholar
• Constenla D, Ortega-Barría E, Rheingans RD, Antil L, Sáez-Llorens X. [Economic impact of rotavirus vaccination in Panama]. An Pediatr (Barc) 2008; 68:128 - 35; http://dx.doi.org/10.1157/13116227; PMID: 18341878
   PubMedGoogle Scholar
• Clark AD, Walker DG, Mosqueira NR, Penny ME, Lanata CF, Fox-Rushby J, et al. Cost-effectiveness of rotavirus vaccination in peru. J Infect Dis 2009; 200:Suppl 1 S114 - 24; http://dx.doi.org/10.1086/605043; PMID: 19817591
   PubMedGoogle Scholar
• Constenla D, Pérez-Schael I, Rheingans RD, Antil L, Salas H, Yarzábal JP. [Assessment of the economic impact of the antiretroviral vaccine in Venezuela]. Rev Panam Salud Publica 2006; 20:213 - 22; http://dx.doi.org/10.1590/S1020-49892006000900001; PMID: 17316479
   PubMedGoogle Scholar
• Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007; 21:205 - 16; http://dx.doi.org/10.1590/S1020-49892007000300003; PMID: 17612464
   PubMed Web of Science ®Google Scholar
• Newall AT, Beutels P, Macartney K, Wood J, MacIntyre CR. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 2007; 25:8851 - 60; http://dx.doi.org/10.1016/j.vaccine.2007.10.009; PMID: 18022735
   PubMed Web of Science ®Google Scholar
• Wang XY, Riewpaiboon A, von Seidlein L, Chen XB, Kilgore PE, Ma JC, et al. Potential cost-effectiveness of a rotavirus immunization program in rural China. Clin Infect Dis 2009; 49:1202 - 10; http://dx.doi.org/10.1086/605632; PMID: 19739973
   PubMed Web of Science ®Google Scholar
• Ho AM, Nelson EA, Walker DG. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective. Arch Dis Child 2008; 93:52 - 8; http://dx.doi.org/10.1136/adc.2007.117879; PMID: 17855438
   PubMed Web of Science ®Google Scholar
• Rose J, Hawthorn RL, Watts B, Singer ME. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ 2009; 339:b3653 - 65; http://dx.doi.org/10.1136/bmj.b3653; PMID: 19783581
   PubMed Web of Science ®Google Scholar
• Esposito DH, Tate JE, Kang G, Parashar UD. Projected impact and cost-effectiveness of a rotavirus vaccination program in India, 2008. Clin Infect Dis 2011; 52:171 - 7; http://dx.doi.org/10.1093/cid/ciq094; PMID: 21288839
   PubMed Web of Science ®Google Scholar
• Chodick G, Waisbourd-Zinman O, Shalev V, Kokia E, Rabinovich M, Ashkenazi S. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel. Eur J Public Health 2009; 19:254 - 9; http://dx.doi.org/10.1093/eurpub/ckp005; PMID: 19221026
   PubMed Web of Science ®Google Scholar
• Igarashi A, Fukuda T, Orihara S, Suzuki H. TSutani K. Cost-utility analysis of rotavirus vaccine (Rotarix) in Japan. Value Health 2009; 12:A429; http://dx.doi.org/10.1016/S1098-3015(10)75119-6
   Google Scholar
• Kang HY, Kim KH, Kim JH, Kim HM, Kim JK, Kim MS, et al. Public Health and Economic Impact of Rotavirus Vaccination in Korea. Value Health 2010; 13:A549; http://dx.doi.org/10.1016/S1098-3015(11)73294-6
   Google Scholar
• Flem ET, Latipov R, Nurmatov ZS, Xue Y, Kasymbekova KT, Rheingans RD. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan. J Infect Dis 2009; 200:Suppl 1 S195 - 202; http://dx.doi.org/10.1086/605040; PMID: 19817600
   PubMedGoogle Scholar
• Milne RJ, Grimwood K. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule. Value Health 2009; 12:888 - 98; http://dx.doi.org/10.1111/j.1524-4733.2009.00534.x; PMID: 19490550
   PubMed Web of Science ®Google Scholar
• Wu CL, Yang YC, Huang LM, Chen KT. Cost-effectiveness of childhood rotavirus vaccination in Taiwan. Vaccine 2009; 27:1492 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.01.023; PMID: 19186200
   PubMed Web of Science ®Google Scholar
• Chotivitayatarakorn P, Chotivitayatarakorn P, Poovorawan Y. Cost-effectiveness of rotavirus vaccination as part of the national immunization program for Thai children. Southeast Asian J Trop Med Public Health 2010; 41:114 - 25; PMID: 20578490
   PubMed Web of Science ®Google Scholar
• Isakbaeva ET, Musabaev E, Antil L, Rheingans R, Juraev R, Glass RI, et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007; 25:373 - 80; http://dx.doi.org/10.1016/j.vaccine.2006.07.029; PMID: 16930784
   PubMed Web of Science ®Google Scholar
• Fischer TK, Anh DD, Antil L, Cat ND, Kilgore PE, Thiem VD, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005; 192:1720 - 6; http://dx.doi.org/10.1086/497339; PMID: 16235169
   PubMed Web of Science ®Google Scholar
• Kim SY, Goldie SJ, Salomon JA. Cost–effectiveness of rotavirus vaccination in Vietnam. BMC Public Health 2009; 9:29; http://dx.doi.org/10.1186/1471-2458-9-29; PMID: 19159483
   PubMed Web of Science ®Google Scholar
• Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005; 192:Suppl 1 S133 - 45; http://dx.doi.org/10.1086/431513; PMID: 16088797
   PubMed Web of Science ®Google Scholar
• Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007; 119:684 - 97; http://dx.doi.org/10.1542/peds.2006-2876; PMID: 17403839
   PubMed Web of Science ®Google Scholar
• Shim E, Galvani AP. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine 2009; 27:4025 - 30; http://dx.doi.org/10.1016/j.vaccine.2009.04.030; PMID: 19389452
   PubMed Web of Science ®Google Scholar
• Weycker D, Sofrygin O, Kemner JE, Pelton SI, Oster G. Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq. Vaccine 2009; 27:4930 - 7; http://dx.doi.org/10.1016/j.vaccine.2009.06.025; PMID: 19555715
   PubMed Web of Science ®Google Scholar
• Ortega O, El-Sayed N, Sanders JW, Abd-Rabou Z, Antil L, Bresee J, et al. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt. J Infect Dis 2009; 200:Suppl 1 S92 - 8; http://dx.doi.org/10.1086/605057; PMID: 19817621
   PubMedGoogle Scholar
• Tate JE, Rheingans RD, O’Reilly CE, Obonyo B, Burton DC, Tornheim JA, et al. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in kenya. J Infect Dis 2009; 200:Suppl 1 S76 - 84; http://dx.doi.org/10.1086/605058; PMID: 19817618
   PubMed Web of Science ®Google Scholar
• Berry SA, Johns B, Shih C, Berry AA, Walker DG. The cost-effectiveness of rotavirus vaccination in Malawi. J Infect Dis 2010; 202:Suppl S108 - 15; http://dx.doi.org/10.1086/653578; PMID: 20684689
   PubMed Web of Science ®Google Scholar
• Tate JE, Kisakye A, Mugyenyi P, Kizza D, Odiit A, Braka F. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda. Vaccine 2011; 29:3329 - 34; http://dx.doi.org/10.1016/j.vaccine.2010.12.122; PMID: 21241733
   PubMed Web of Science ®Google Scholar
• Rheingans RD, Antil L, Dreibelbis R, Podewils LJ, Bresee JS, Parashar UD. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis 2009; 200:Suppl 1 S16 - 27; http://dx.doi.org/10.1086/605026; PMID: 19817595
   PubMed Web of Science ®Google Scholar
• Atherly D, Dreibelbis R, Parashar UD, Levin C, Wecker J, Rheingans RD. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis 2009; 200:Suppl 1 S28 - 38; http://dx.doi.org/10.1086/605033; PMID: 19817610
   PubMedGoogle Scholar
• Toumi M, Vesikari T, Giaquinto C. Comment on the contribution by Weycker et al., “Cost of routine immunization of young children against rotavirus infection with Rotarix ® versus RotaTeq ®”. Vaccine 2010; 28:7241; http://dx.doi.org/10.1016/j.vaccine.2010.08.086; PMID: 20831915
   PubMed Web of Science ®Google Scholar
• Giaquinto C, Dominiak-Felden G, Van Damme P, Myint TT, Maldonado YA, Spoulou V, et al. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries. Hum Vaccin 2011; 7:734 - 48; http://dx.doi.org/10.4161/hv.7.7.15511; PMID: 21734466
   PubMed Web of Science ®Google Scholar
• Gray J, Vesikari T, Van Damme P, Giaquinto C, Mrukowicz J, Guarino A, et al. Rotavirus. J Pediatr Gastroenterol Nutr 2008; 46:Suppl 2 S24 - 31; http://dx.doi.org/10.1097/MPG.0b013e31816f78ee; PMID: 18460969
   PubMed Web of Science ®Google Scholar
• Pitzer VE, Viboud C, Lopman BA, Patel MM, Parashar UD, Grenfell BT. Influence of birth rates and transmission rates on the global seasonality of rotavirus incidence. J R Soc Interface 2011; 8:1584 - 93; http://dx.doi.org/10.1098/rsif.2011.0062; PMID: 21508015
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al, Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23 - 33; http://dx.doi.org/10.1056/NEJMoa052664; PMID: 16394299
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, et al, Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11 - 22; http://dx.doi.org/10.1056/NEJMoa052434; PMID: 16394298
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Puustinen L, Zeng SQ, Szakal ED, Delem A, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004; 23:937 - 43; http://dx.doi.org/10.1097/01.inf.0000141722.10130.50; PMID: 15602194
   PubMed Web of Science ®Google Scholar
• Lopman BA, Pitzer VE, Sarkar R, Gladstone B, Patel M, Glasser J, et al. Understanding reduced rotavirus vaccine efficacy in low socio-economic settings. PLoS One 2012; 7:e41720; http://dx.doi.org/10.1371/journal.pone.0041720; PMID: 22879893
   PubMed Web of Science ®Google Scholar
• Gladstone BP, Ramani S, Mukhopadhya I, Muliyil J, Sarkar R, Rehman AM, et al. Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med 2011; 365:337 - 46; http://dx.doi.org/10.1056/NEJMoa1006261; PMID: 21793745
   PubMed Web of Science ®Google Scholar
• Dennehy PH, Vesikari T, Matson DO, Itzler RF, Dallas MJ, Goveia MG, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Hum Vaccin 2011; 7:563 - 8; http://dx.doi.org/10.4161/hv.7.5.15406; PMID: 21441783
   PubMed Web of Science ®Google Scholar
• Van Damme P, Giaquinto C, Huet F, Gothefors L, Maxwell M, Van der Wielen M, REVEAL Study Group. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 2007; 195:Suppl 1 S4 - 16; http://dx.doi.org/10.1086/516714; PMID: 17387650
   PubMed Web of Science ®Google Scholar
• Van Damme P, Giaquinto C, Maxwell M, Todd P, Van der Wielen M, REVEAL Study Group. Distribution of rotavirus genotypes in Europe, 2004-2005: the REVEAL Study. J Infect Dis 2007; 195:Suppl 1 S17 - 25; http://dx.doi.org/10.1086/516715; PMID: 17387648
   PubMedGoogle Scholar
• Bruijning-Verhagen P, Quach C, Bonten M. Nosocomial rotavirus infections: a meta-analysis. Pediatrics 2012; 129:e1011 - 9; http://dx.doi.org/10.1542/peds.2011-2779; PMID: 22392170
   PubMed Web of Science ®Google Scholar
• Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan 2006; 21:402 - 8; http://dx.doi.org/10.1093/heapol/czl018; PMID: 16877455
   PubMed Web of Science ®Google Scholar
• Shepard DS. Cost-effectiveness in Health and Medicine. By M.R. Gold, J.E Siegel, L.B. Russell, and M.C. Weinstein (eds). New York: Oxford University Press, 1996. J Ment Health Policy Econ. 1999 Jun 1;2(2):91-92.
   Google Scholar
• Brisson M, Sénécal M, Drolet M, Mansi JA. Health-related quality of life lost to rotavirus-associated gastroenteritis in children and their parents: a Canadian prospective study. Pediatr Infect Dis J 2010; 29:73 - 5; http://dx.doi.org/10.1097/INF.0b013e3181b41506; PMID: 19907361
   PubMed Web of Science ®Google Scholar
• Huppertz HI, Forster J, Heininger U, Roos R, Neumann HU, Hammerschmidt T. The parental appraisal of the morbidity of diarrhea in infants and toddlers (PAMODI) survey. Clin Pediatr (Phila) 2008; 47:363 - 71; http://dx.doi.org/10.1177/0009922807310933; PMID: 18270310
   PubMed Web of Science ®Google Scholar
• Haagsma JA, Havelaar AH, Janssen BM, Bonsel GJ. Disability adjusted life years and minimal disease: application of a preference-based relevance criterion to rank enteric pathogens. Popul Health Metr 2008; 6:7; http://dx.doi.org/10.1186/1478-7954-6-7; PMID: 19114007
   PubMedGoogle Scholar
• Martin A, Cottrell S, Standaert B. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. J Med Econ 2008; 11:471 - 84; http://dx.doi.org/10.3111/13696990802321047; PMID: 19450099
   PubMedGoogle Scholar
• Payne DC, Staat MA, Edwards KM, Szilagyi PG, Weinberg GA, Hall CB, et al, New Vaccine Surveillance Network (NVSN). Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis 2011; 53:245 - 53; http://dx.doi.org/10.1093/cid/cir307; PMID: 21705316
   PubMed Web of Science ®Google Scholar
• Van Effelterre T, Soriano-Gabarró M, Debrus S, Claire Newbern E, Gray J. A mathematical model of the indirect effects of rotavirus vaccination. Epidemiol Infect 2010; 138:884 - 97; http://dx.doi.org/10.1017/S0950268809991245; PMID: 20028612
   PubMed Web of Science ®Google Scholar
• Atkins KE, Shim E, Pitzer VE, Galvani AP. Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine 2012; 30:552 - 64; http://dx.doi.org/10.1016/j.vaccine.2011.11.064; PMID: 22133508
   PubMed Web of Science ®Google Scholar
• Atchison C, Lopman B, Edmunds WJ. Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine 2010; 28:3118 - 26; http://dx.doi.org/10.1016/j.vaccine.2010.02.060; PMID: 20197142
   PubMed Web of Science ®Google Scholar
• Cortese MM, Parashar UD, Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). [Erratum in: MMWR Recomm Rep. 2010 Aug 27;59] [33] MMWR Recomm Rep 2009; 58:RR-2 1 - 25; PMID: 19194371
   PubMedGoogle Scholar
• Ciarlet M, Schödel F. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq. Vaccine 2009; 27:Suppl 6 G72 - 81; http://dx.doi.org/10.1016/j.vaccine.2009.09.107; PMID: 20006144
   PubMedGoogle Scholar
• Iturriza-Gómara M, Dallman T, Bányai K, Böttiger B, Buesa J, Diedrich S, et al. Rotavirus genotypes co-circulating in Europe between 2006 and 2009 as determined by EuroRotaNet, a pan-European collaborative strain surveillance network. Epidemiol Infect 2011; 139:895 - 909; http://dx.doi.org/10.1017/S0950268810001810; PMID: 20707941
   PubMed Web of Science ®Google Scholar
• Pitzer VE, Patel MM, Lopman BA, Viboud C, Parashar UD, Grenfell BT. Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions. Proc Natl Acad Sci U S A 2011; 108:19353 - 8; http://dx.doi.org/10.1073/pnas.1110507108; PMID: 22084114
   PubMed Web of Science ®Google Scholar
• Clark HF, Lawley D, DiStefano D, Matthijnssens J, Dinubile MJ. Distribution of rotavirus genotypes causing nosocomial and community-acquired acute gastroenteritis at the Children’s Hospital of Philadelphia in the new rotavirus vaccine era. Hum Vaccin 2011; 7:1118 - 23; http://dx.doi.org/10.4161/hv.7.11.17820; PMID: 22048265
   PubMed Web of Science ®Google Scholar
• Vesikari T, Ujari M, Renko M, Hemming M, Risku M, Salminen M, et al. Results from 2 years of surveillance of hospitalised children with acute gastroenteritis following introduction of routine rotavirus vaccination in Finland. 30th Annual Meeting of the European Society For Paediatric Infectious Diseases.Thessaloniki, Greece, May 8 - 12, 2012, 2012, p. 1-2.
   Google Scholar
• Paulke-Korinek M, Kundi M, Rendi-Wagner P, de Martin A, Eder G, Schmidle-Loss B, et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011; 29:2791 - 6; http://dx.doi.org/10.1016/j.vaccine.2011.01.104; PMID: 21320539
   PubMed Web of Science ®Google Scholar
• Braeckman T, Van Herck K, Raes M, Vergison A, Sabbe M, Van Damme P. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 2011; 30:Suppl S21 - 4; http://dx.doi.org/10.1097/INF.0b013e3181fefc51; PMID: 21183836
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al, Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23 - 33; http://dx.doi.org/10.1056/NEJMoa052664; PMID: 16394299
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J 2010; 29:957 - 63; http://dx.doi.org/10.1097/INF.0b013e3181e28e6e; PMID: 20442684
   PubMed Web of Science ®Google Scholar
• Castilla J, Beristain X, Martínez-Artola V, Navascués A, García Cenoz M, Alvarez N, et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. Vaccine 2012; 30:539 - 43; http://dx.doi.org/10.1016/j.vaccine.2011.11.071; PMID: 22122860
   PubMed Web of Science ®Google Scholar
• Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301:2243 - 51; http://dx.doi.org/10.1001/jama.2009.756; PMID: 19491186
   PubMed Web of Science ®Google Scholar
• Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993; 2:169 - 80; http://dx.doi.org/10.1007/BF00435221; PMID: 8401453
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press (1996)
   Google Scholar
• Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993; 2:169 - 80; http://dx.doi.org/10.1007/BF00435221; PMID: 8401453
   PubMed Web of Science ®Google Scholar